<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922645</url>
  </required_header>
  <id_info>
    <org_study_id>USRC-2021-001</org_study_id>
    <nct_id>NCT04922645</nct_id>
  </id_info>
  <brief_title>Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>A Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Impact of Auryxia (Ferric Citrate) on Erythropoiesis-Stimulating Agent (ESA) Use, Intravenous (IV) Iron Use, Phosphate Control, and Anemia Control in Adult Participants on In-Center Hemodialysis or Home Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>USRC Kidney Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akebia Therapeutics Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>USRC Kidney Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to demonstrate the effect of Auryxia, when used as the primary&#xD;
      phosphate lowering therapy, on the overall cumulative use of erythropoiesis-stimulating agent&#xD;
      and intravenous iron as well as on the laboratory parameters indicative of phosphate and&#xD;
      anemia management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 200 participants will be randomized 1:1 (stratified by modality and hemoglobin&#xD;
      level) to receive either Auryxia or standard of care phosphate lowering therapy to determine&#xD;
      the impact of Auryxia when used as the primary phosphate lowering therapy as compared to&#xD;
      standard of care on the utilization of erythropoiesis-stimulating agent and intravenous iron&#xD;
      in both in-center and home dialysis populations. This study will also seek to determine the&#xD;
      impact of Auryxia, when used as the primary phosphate lowering therapy versus standard of&#xD;
      care, on the biochemical assessments of serum phosphate and hemoglobin in both in-center and&#xD;
      home dialysis populations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in mean dose of erythropoiesis-stimulating agent (standardized Units per month) between Auryxia and standard of care treatment groups</measure>
    <time_frame>Baseline period (Month -3 to Day 1) to months 4to 6 (efficacy evaluation period)</time_frame>
    <description>Difference in change from baseline period (Month -3 to Day 1) to months 4 to 6 (efficacy evaluation period) in mean dose of erythropoiesis-stimulating agent (standardized Units per month) between Auryxia and standard of care treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in mean dose of intravenous iron (milligram per month) between Auryxia and standard of care treatment groups.</measure>
    <time_frame>Baseline period (Month -3 to Day 1) to months 4 to6 (efficacy evaluation period)</time_frame>
    <description>Difference in change from baseline period to efficacy evaluation period in mean dose of intravenous iron (milligrams per month) between Auryxia and standard of care treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in hemoglobin measurements</measure>
    <time_frame>Baseline period (Month -3 to Day 1) to months 4to6 (efficacy evaluation period).</time_frame>
    <description>Difference in proportion of measurements with hemoglobin at or above 10.0 grams per deciliter between Auryxia and standard of care treatment groups during efficacy evaluation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in serum phosphate measurements</measure>
    <time_frame>Baseline period (Month -3 to Day 1) to months 4to6 (efficacy evaluation period)</time_frame>
    <description>Difference in proportion of measurements with serum phosphate at or below 5.5 milligrams per deciliter between Auryxia and standard of care treatment groups during efficacy evaluation period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperphosphatemia</condition>
  <condition>Anemia, Iron Deficiency</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Ferric citrate (commercially available, Auryxia)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric citrate, (commercially available Auryxia), supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron). Administered orally with meals or snacks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care phosphate lowering therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-Auryxia phosphate-lowering therapy administered as standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Citrate 1 gram Oral Tablet</intervention_name>
    <description>Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).</description>
    <arm_group_label>Ferric citrate (commercially available, Auryxia)</arm_group_label>
    <other_name>Auryxia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care phosphate-lowering therapy</intervention_name>
    <description>Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.</description>
    <arm_group_label>Standard of care phosphate lowering therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult participants greater or equal to 18 years old.&#xD;
&#xD;
          2. Diagnosis of end-stage kidney disease and receiving maintenance dialysis (in-center,&#xD;
             home hemodialysis or peritoneal dialysis) for greater or equal to 12 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          3. Most recent transferrin saturation less than or equal to 50 percent&#xD;
&#xD;
          4. Most recent serum phosphate is greater or equal to 3.0 milligrams per deciliter&#xD;
&#xD;
          5. Receiving treatment for greater or equal to 8 weeks prior to screening with&#xD;
             non-Auryxia phosphate lowering therapy. No requirement for stable dosing within this&#xD;
             time frame.&#xD;
&#xD;
          6. Receiving treatment for greater or equal to 8 weeks prior to screening with&#xD;
             erythropoiesis-stimulating agent (any dose, any type). No requirement for stable&#xD;
             dosing within this time frame.&#xD;
&#xD;
          7. Understands the procedures and requirements of the study and provides written informed&#xD;
             consent and authorization for protected health information disclosure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A known allergy or intolerance to Auryxia or any of its constituents.&#xD;
&#xD;
          2. Hypersensitivity reaction to previous oral iron therapy.&#xD;
&#xD;
          3. History of hemochromatosis or other iron overload syndrome.&#xD;
&#xD;
          4. Active malignancy requiring current treatment except for non-melanoma skin cancer&#xD;
             regardless of treatment.&#xD;
&#xD;
          5. Active drug or alcohol dependence or abuse (excluding tobacco use or medicinal or&#xD;
             recreational marijuana) within the 12 months prior to Screening or evidence of such&#xD;
             abuse (in the opinion of the Investigator).&#xD;
&#xD;
          6. Limited life expectancy (less than 6 months), (in the opinion of the Investigator).&#xD;
&#xD;
          7. Scheduled organ transplant and participants on the kidney transplant wait-list who are&#xD;
             expected to receive a transplant within 6 months of screening. Being active on&#xD;
             transplant list is not an exclusion. Previous kidney transplant is not an exclusion.&#xD;
&#xD;
          8. Unable to comply with study requirements or in the opinion of the Investigator not&#xD;
             clinically stable to participate in the study.&#xD;
&#xD;
          9. Females who are known to be pregnant or are breast-feeding during Screening or are&#xD;
             planning to become pregnant and breastfeeding during the study period.&#xD;
&#xD;
         10. Evidence of clinically active infection at the time of Screening.&#xD;
&#xD;
         11. Use of an investigational medication or participation in an investigational study&#xD;
             within 30 days prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martha Block, RN</last_name>
    <phone>720-591-2533</phone>
    <email>Martha.Block@usrenalcare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Brillhart, MSCI</last_name>
    <phone>303-881-9451</phone>
    <email>Stephanie.Brillhart@usrenalcare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>US Renal Care - Dimond</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99515</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Mesa</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Pine Bluff</name>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <zip>71603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Northridge Roscoe</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-8451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Dalton</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Major Health</name>
      <address>
        <city>Shelbyville</city>
        <state>Indiana</state>
        <zip>46176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Red Rocks</name>
      <address>
        <city>Gallup</city>
        <state>New Mexico</state>
        <zip>87301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - North Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dallas Renal Group</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Houston Street</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Palo Alto</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Pleasanton Rd.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>US Renal Care - Westover Hills</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brillhart</last_name>
      <phone>303-881-9451</phone>
      <email>stephanie.brillhart@usrenalcare.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

